Hennessy Advisors Inc increased International Business Machs Com (IBM) stake by 7.27% reported in 2019Q1 SEC filing. Hennessy Advisors Inc acquired 6,954 shares as International Business Machs Com (IBM)’s stock declined 2.27%. The Hennessy Advisors Inc holds 102,550 shares with $14.47 million value, up from 95,596 last quarter. International Business Machs Com now has $123.42B valuation. The stock increased 0.25% or $0.35 during the last trading session, reaching $139.2. About 5.29 million shares traded or 54.43% up from the average. International Business Machines Corporation (NYSE:IBM) has declined 6.86% since June 23, 2018 and is downtrending. It has underperformed by 11.29% the S&P500. Some Historical IBM News: 16/05/2018 – IBM Study: Majority of Businesses View GDPR as Opportunity to Improve Data Privacy and Security; 04/04/2018 – How IBM’s game show winning supercomputer is solving problems before they occur; 11/04/2018 – Pelco and IBM Combine Powerful Camera and Video Management Systems Technology with Intelligent Video Analytics; 30/03/2018 – IBM sees quantum computing going mainstream within five years; 24/05/2018 – IBM Leads ‘Call for Code’ to Use Cloud, Data, Al, Blockchain for Natural Disaster Relief; 21/03/2018 – IBM: Morgan Stanley Cheers Display of Watson Success at ‘Think’ Conference — Barron’s Blog; 22/05/2018 – College students apply for more entry-level jobs at IBM, JP Morgan, Amazon and Tesla than at any other companies; 06/03/2018 – Wandera Joins MaaS360 on IBM Security App Exchange with Mobile Security Integration; 16/04/2018 – MARSH – CO IS DEVELOPING COMMERCIAL PROOF OF INSURANCE SOLUTION IN CONJUNCTION WITH IBM, WITH INPUT FROM ACORD, CUSTOMER FEEDBACK FROM ISN; 24/04/2018 – IBM IBM.N SETS REGULAR QUARTERLY CASH DIVIDEND OF $1.57/SHR
Among 2 analysts covering RedHill Biopharma (NASDAQ:RDHL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma has $17 highest and $16 lowest target. $16.50’s average target is 142.29% above currents $6.81 stock price. RedHill Biopharma had 5 analyst reports since February 27, 2019 according to SRatingsIntel. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by H.C. Wainwright on Wednesday, February 27. The firm has “Buy” rating by WBB Securities given on Tuesday, March 12. See RedHill Biopharma Ltd. (NASDAQ:RDHL) latest ratings:
25/05/2019 Broker: BidaskScore Rating: Hold Upgrade
06/05/2019 Broker: BidaskScore Rating: Sell Downgrade
17/03/2019 Broker: BidaskScore Rating: Hold Upgrade
12/03/2019 Broker: WBB Securities Old Rating: Speculative Buy New Rating: Buy New Target: $17 Upgrade
27/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $16 Maintain
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $194.04 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn’s disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.
More notable recent RedHill Biopharma Ltd. (NASDAQ:RDHL) news were published by: Nasdaq.com which released: “RedHill Biopharma Receives Allowance for New US Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections – Nasdaq” on June 10, 2019, also Nasdaq.com with their article: “RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer – Nasdaq” published on May 28, 2019, Seekingalpha.com published: “RedHill Biopharma And Talicia: The NDA – Seeking Alpha” on May 31, 2019. More interesting news about RedHill Biopharma Ltd. (NASDAQ:RDHL) were released by: Bizjournals.com and their article: “She left one Triangle public company to become CSO of another local public pharma – Triangle Business Journal” published on May 29, 2019 as well as Globenewswire.com‘s news article titled: “RedHill Biopharma to Present at Three Conferences in April – GlobeNewswire” with publication date: April 04, 2019.
The stock decreased 1.16% or $0.08 during the last trading session, reaching $6.81. About 29,259 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has risen 11.92% since June 23, 2018 and is uptrending. It has outperformed by 7.49% the S&P500. Some Historical RDHL News: 04/05/2018 – RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection; 04/05/2018 – REDHILL BIOPHARMA SEES FILING US NDA FOR TALICIA EARLY 2019; 08/05/2018 – REDHILL BIOPHARMA – DOES NOT HAVE PLANS TO RAISE ADDITIONAL CAPITAL AHEAD OF MAP US PHASE lll STUDY TOP-LINE RESULTS WITH RHB-104 FOR CROHN’S DISEASE; 19/03/2018 – RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting; 07/05/2018 – RedHill Biopharma: Top-Line Results From the Phase III Study With RHB-104 for Crohn’s Disease Seen in 3 Mo; 09/04/2018 – REDHILL SEES QUARTER OVER QUARTER NET REV. GROWTH; 19/03/2018 – RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual M; 14/05/2018 – REDHILL BIOPHARMA SEES RHB-104 TOP-LINE RESULTS IN ABOUT 3 MOS; 30/05/2018 – RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018; 10/04/2018 – Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications
Investors sentiment increased to 1.03 in Q1 2019. Its up 0.44, from 0.59 in 2018Q4. It is positive, as 67 investors sold IBM shares while 524 reduced holdings. 142 funds opened positions while 468 raised stakes. 473.01 million shares or 9.66% less from 523.62 million shares in 2018Q4 were reported. Chesley Taft And Ltd Liability Co holds 37,583 shares. The Illinois-based Pekin Hardy Strauss has invested 0.07% in International Business Machines Corporation (NYSE:IBM). Baldwin Investment accumulated 0.08% or 1,969 shares. American Ser holds 6.85% of its portfolio in International Business Machines Corporation (NYSE:IBM) for 152,651 shares. Knott David M invested in 4,284 shares. Pillar Pacific Capital Management Limited Liability Corp reported 38,006 shares. D Scott Neal Inc has 0.17% invested in International Business Machines Corporation (NYSE:IBM). Culbertson A N Company Incorporated accumulated 22,543 shares. American Rech Mngmt reported 5.65% in International Business Machines Corporation (NYSE:IBM). Federated Invsts Incorporated Pa holds 0.03% or 88,312 shares. Rockland has invested 0.24% in International Business Machines Corporation (NYSE:IBM). Windsor Mngmt Limited Com invested in 2,520 shares or 0.17% of the stock. Massachusetts-based Renaissance Inv Group has invested 0.53% in International Business Machines Corporation (NYSE:IBM). Supplemental Annuity Collective Tru Of Nj holds 0.5% of its portfolio in International Business Machines Corporation (NYSE:IBM) for 8,000 shares. Willingdon Wealth owns 37,313 shares.
More notable recent International Business Machines Corporation (NYSE:IBM) news were published by: Finance.Yahoo.com which released: “Better Buy: Google vs. IBM – Yahoo Finance” on June 21, 2019, also Seekingalpha.com with their article: “IBM: Why I See Upside – Seeking Alpha” published on June 20, 2019, Finance.Yahoo.com published: “IBM Develops World’s Most Powerful Commercial Supercomputer for Total – Yahoo Finance” on June 18, 2019. More interesting news about International Business Machines Corporation (NYSE:IBM) were released by: Finance.Yahoo.com and their article: “The New Oracle Looks Like the Old IBM – Yahoo Finance” published on June 20, 2019 as well as Finance.Yahoo.com‘s news article titled: “Hereâ€™s What Hedge Funds Think About International Business Machines Corp. (IBM) – Yahoo Finance” with publication date: June 10, 2019.
Among 4 analysts covering Int`l Business Machines (NYSE:IBM), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Int`l Business Machines had 6 analyst reports since March 8, 2019 according to SRatingsIntel. The stock of International Business Machines Corporation (NYSE:IBM) earned “Neutral” rating by Citigroup on Wednesday, April 17. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, April 17 report.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
.(tagsToTranslate)International Business Machines Corporation(t)International Business Machines Corporation – (NYSE:IBM)(t)NYSE:IBM(t)Stock News(t)13F(t)Insitutional Ownership Change(t)RedHill Biopharma Ltd.(t)RedHill Biopharma Ltd. – (NASDAQ:RDHL)(t)NASDAQ:RDHL(t)Ratings Sentiment(t)Weekly Ratings(t)Analyst Ratings
This is a syndicated post. Read the original post at Source link .